Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Cerenome (Nasdaq: CNSY) announced that its wholly owned subsidiary, CNSide Diagnostics, has selected XiFin Empower RCM to provide billing and clearinghouse services for the CNSide cerebrospinal fluid assay platform. Cerenome expects to begin billing through XiFin in Q3 2026, including an accumulated backlog of CNSide tests.
According to Cerenome, XiFin’s AI-driven platform offers end-to-end revenue cycle capabilities and scalable automation to support higher test volumes without proportional administrative cost. The move follows expanded commercial and Medicare Advantage payer coverage for CNSide and is intended to help improve claim quality, reduce days sales outstanding, and support revenue and profitability goals.
Cerenome (Nasdaq: PSTV, transitioning to CNSY) announced completion of its corporate rebrand from Plus Therapeutics, effective August 3, 2026, when its name will become Cerenome and its stock will begin trading under ticker “CNSY” on the Nasdaq Capital Market.
The company positions itself as an integrated CNS oncology business combining precision diagnostics, targeted therapeutics and proprietary data. Key assets include the commercially available CNSide cerebrospinal fluid diagnostic, lead investigational radiotherapeutic REYOBIQ for multiple CNS cancers, and a data analytics/artificial intelligence platform, including a partnership with Ephemeral Technologies. Existing CNSide and REYOBIQ brands remain unchanged, and the name/ticker changes do not affect shareholder ownership.
Plus Therapeutics (Nasdaq: PSTV) will feature two scientific posters and a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference, held August 13–15, 2026, in Boston. The presentations highlight the Company’s ReSPECT-LM clinical development program with rhenium obisbemeda and its CNSide® cerebrospinal fluid diagnostic platform.
Plus Therapeutics and wholly owned subsidiary CNSide Diagnostics will also host a one-hour symposium on August 13 titled “Redefining the Management of Leptomeningeal Metastases,” and plan to introduce the new Cerenome brand and expanded CNS cancer focus. Posters will later be posted on the Company’s website.
Plus Therapeutics (Nasdaq: PSTV), through its wholly owned subsidiary CNSide Diagnostics, signed a regional coverage agreement with Medical Mutual effective July 1, 2026. The agreement covers approximately 1.2 million people across Ohio and Kentucky for the CNSide® cerebrospinal fluid Tumor Cell Enumeration assay, increasing total contracted coverage to about 127 million people.
The CNSide® CSF Assay Platform is used for rapid diagnosis, treatment monitoring, and guidance in leptomeningeal metastases. According to Plus Therapeutics, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, with reported sensitivity of 92%, specificity of 95%, and influence on treatment decisions in 90% of cases.
Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative to integrate GTC next-generation sequencing into the CNSide cerebrospinal fluid assay. The partnership is expected to enable comprehensive DNA and RNA profiling across hundreds of biomarkers from a single CSF specimen, adding a guideline-recognized nucleic acid layer to CNSide’s established circulating tumor cell enumeration.
According to Plus Therapeutics, the move aligns CNSide with updated NCCN CNS Cancers Guidelines (Version 2.2026), supports its three-pillar CNS oncology strategy, and leverages GTC sequencing as a technical service to the CNSide CLIA lab. CNSide already holds AMA PLA code 0640U effective July 1, 2026, is enrolled with Medicare, and has commercial payer coverage of about 126 million U.S. lives. A health-economic analysis associated CNSide-enabled earlier LM management with roughly a 40% reduction in LM-related healthcare costs, and Plus cites an estimated U.S. LM addressable population above 100,000 patients annually.
Plus Therapeutics (Nasdaq: PSTV) highlighted an update to the NCCN CNS Cancers Guidelines that continues to endorse cerebrospinal fluid (CSF) analysis and recommends CSF cytology follow-up every 4–8 weeks for leptomeningeal metastases (LM) patients receiving intrathecal therapy, alongside MRI and clinical evaluation.
The company positioned its CNSide CSF assay as aligned with this framework, citing FORESEE study data where CNSide more than doubled LM tumor-detection sensitivity versus cytology in matched samples and previously reported health economics data suggesting ~40% LM-related cost reductions. In 2026, CNSide secured Medicare enrollment, CAP accreditation, expanded payer coverage including Blue Shield of California and Elevance Health, reaching about 126 million covered lives, with stated 2026 goals of 150 million covered lives and 1,250 total CNSide tests.
Plus Therapeutics (Nasdaq: PSTV) will rebrand as Cerenome and begin trading as CNSY on August 3, 2026, while affirming 2026 milestone guidance.
Key updates include REYOBIQ trial and manufacturing progress, rapid CNSide payer and test-volume growth, Medicare enrollment, a new PLA billing code, and an AI/data partnership with Ephemeral Technologies.
Plus Therapeutics (Nasdaq:PSTV) subsidiary CNSide Diagnostics signed a national agreement with Elevance Health, effective May 1, 2026, adding coverage for about 45.4 million people and raising total CNSide® CSF TCE assay contracted coverage to 126 million.
The CNSide® platform supports diagnosis and management of leptomeningeal metastases, with over 11,000 tests run at more than 120 U.S. cancer institutions since 2020. Reported performance includes 92% sensitivity, 95% specificity, and influence on treatment decisions in 90% of cases, supported by 9 peer-reviewed publications and the FORESEE clinical trial.
Plus Therapeutics (Nasdaq:PSTV) will host a business update conference call and webcast on June 30, 2026 at 8:30 a.m. ET. Management plans to discuss the CNSide® diagnostic launch, the integrated development plan for lead drug Reyobiq, CNS oncology strategy, and native artificial intelligence initiatives.
Plus Therapeutics (Nasdaq:PSTV) announced that its wholly owned subsidiary CNSide Diagnostics has received CAP accreditation for its Houston clinical laboratory, complementing existing CLIA certification.
The accreditation is expected to support U.S. commercialization of the CNSide® CSF Assay Platform, payor engagement, health system adoption, and future test menu expansion.